Literature DB >> 1860262

Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome.

J F Borel1.   

Abstract

Cyclosporin A (CyA, Sandimmun) is the forerunner of a new generation of immunosuppressive drugs. It is highly effective in both antibody- and cell-mediated immunity and in inhibiting chronic inflammatory reactions. Cyclosporin A is, therefore, widely used to prevent rejection in clinical organ transplantation and appears to be very promising in the treatment of several autoimmune diseases. Cyclosporin A is not only effective when given at the time of sensitization (prevention of disease), but also when administered therapeutically during an immune response, such as during the active course of an autoimmune disease. The most important aspect of its immunosuppressive mechanism is the inhibition of lymphokine production secreted by activated T cells. The pharmacological effects of CyA are rapid in onset, dose-dependent and often quickly reversible when treatment is stopped.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860262

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  17 in total

Review 1.  The cyclosporins.

Authors:  Z Rehácek
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

Review 2.  Molecular and clinical aspects of drug-induced gingival overgrowth.

Authors:  P C Trackman; A Kantarci
Journal:  J Dent Res       Date:  2015-02-13       Impact factor: 6.116

3.  Influence of enalapril on experimental cyclosporin A nephrotoxicity.

Authors:  A Anarat; A Noyan; G Gonlusen; N Duman; D Tuncer
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

Review 4.  Childhood nephrotic syndrome--current and future therapies.

Authors:  Larry A Greenbaum; Rainer Benndorf; William E Smoyer
Journal:  Nat Rev Nephrol       Date:  2012-06-12       Impact factor: 28.314

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Mechanism of action of cyclosporin in rheumatoid arthritis.

Authors:  J Bentin
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

7.  Recurrent nephrotic syndrome after transplantation: early treatment with plasmaphaeresis and cyclophosphamide.

Authors:  P Cochat; A Kassir; S Colon; C Glastre; B Tourniaire; B Parchoux; X Martin; L David
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

8.  Role of calcineurin-mediated dephosphorylation in modulation of an inwardly rectifying K+ channel in human proximal tubule cells.

Authors:  Manabu Kubokawa; Toshiyuki Kojo; You Komagiri; Kazuyoshi Nakamura
Journal:  J Membr Biol       Date:  2009-10-29       Impact factor: 1.843

Review 9.  Immunosuppression for long-term maintenance of renal allograft function.

Authors:  Gerd Offermann
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.

Authors:  J McCauley; R Shapiro; D Ellis; H Igdal; A Tzakis; T E Starzl
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.